Skip to content

FIT in Diverticulitis

Use of Faecal Biomarkers After Acute Diverticulitis: Can They Risk Stratify for Colorectal Cancer?

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06210724
Enrollment
275
Registered
2024-01-18
Start date
2023-10-09
Completion date
2024-10-28
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Diverticulitis

Keywords

Faecal Immunochemical test for haemoglobin, FIT, Faecal calprotectin, Faecal microbiome

Brief summary

Background and study aims Diverticular disease or diverticulosis is a benign disease of the colon. Diverticulae are pockets of bowel wall which protrude through weaknesses in the muscular wall of the colon. The mechanisms leading to their formation remains unclear and is likely a complex interaction of multiple factors. For the majority of people these pockets are incidental findings they can become inflamed which is called diverticulitis. The main aim of this study is to see if a faecal samples, which will be tested for hidden blood content with a faecal immunochemical test for haemoglobin (FIT), could be used as an alternative to currently used follow-up investigations for patients who have an episode of acute diverticulitis confirmed on a computerised tomography (CT) scan. These are colonoscopy, sigmoidoscopy or a special CT called CT colonoscopy. The investigators will also be testing faecal calprotectin which is a marker of bowel inflammation and an assessment of the microbes that live in the bowel to see if this will provide further insights into the diagnosis and treatment of diverticulitis. Who can participate? All patients 18 or over admitted to a participating hospital with acute diverticulitis confirmed on a CT scan and who planned to have one of the currently used follow-up investigations are eligible. What does the study involve? The study will involve participants taking three stool (faecal) samples using faecal testing kits posted to participants. One is as close to their first solid stool after diagnosis as possible, the others are at 3 weeks after diagnosis and then 6 weeks after diagnosis. What are the possible benefits and risks of participating? There are no risks of participating. The investigators hope to demonstrate that a negative FIT test for patients after acute diverticulitis will be able to exclude a bowel cancer and prevent the majority of future patients having invasive and time consuming tests. There no additional benefit for participants for their current episode, as they will still need to have these tests. Where is the study run from? Royal Surrey County Hospital When is the study starting and how long is it expected to run for? 09/10/2023-30/09/2024 Who is funding the study? The study is being funded by MATTU (Minimal Access Therapy Training Unit), GUTS (GUTS - Fighting Bowel Cancer) and NHIR (National Institute for Health and Care Research). Who is the main contact? James Norman, On the study email rsch.colorectalDfitstudy@nhs.net

Detailed description

What is the purpose of the study? The main aim of this study is to see if a faecal immunochemical test (FIT), could be used as an alternative to currently used follow-up investigations, of colonoscopy, flexible sigmoidoscopy or CT (computerised tomography) colonography, for patients who have an episode of acute diverticulitis to exclude a colorectal cancer (CRC). As stated in the ASCPGBI consensus guidelines 2021 the risk of CRC in those with CT diagnosed uncomplicated diverticulitis is 1.6-1.9% and in those with complicated diverticulitis 7.8-10.9%. Our primary aim is to determine whether single, or multiple faecal haemoglobin and faecal calprotectin results after an episode of acute diverticulitis can be used to risk stratify for further investigations to exclude colorectal cancer. Our secondary aims are: To determine whether single, or multiple faecal haemoglobin and faecal calprotectin results after an episode of acute diverticulitis could be used to risk stratify for further investigations to exclude other colonic findings such as high-risk adenoma? Would including demographic factors such as age or anaemia allow better risk stratification? Assess the faecal microbiome in patients with acute diverticulitis and how it changes as inflammation settles. Any antibiotic treatment will also be recorded and the effect on the faecal microbiome analysed. Inclusion criteria: Computerised tomography diagnosis of acute diverticulitis Participants capable of giving informed consent Aged ≥ 18 years Planned for colonoscopy, flexible sigmoidoscopy or CT colonoscopy after diverticulitis diagnosis Exclusion criteria: Paediatric patients (\<18 years) Not provided at least 1 FIT sample Unable to/unwilling to provide informed consent Withdrawal of consent for inclusion in study Previous pan-proctocolectomy, subtotal colectomy surgery, or presence of stoma Diagnosed with colorectal cancer Mental health illness limiting compliance Treated in hospital with colonic resection Did not have colonoscopy, flexible sigmoidoscopy or CT colonoscopy Recruitment: Patients who attend hospital with a diagnosis of acute diverticulitis confirmed on a CT scan and who have had a clinical decision to follow-up with either a colonoscopy, flexible sigmoidoscopy or CT colonography will be approached for written consent to participate. Patients will then be posted a patient information leaflet and a pack with collection devices to take samples at home and post back. The results of their follow-up investigation (colonoscopy, flexible sigmoidoscopy or CT colonography + any histology) will be collected when completed Involvement for patients will involve collecting and posting back in pre-paid envelopes faecal samples on their first solid stool (or as soon as possible after diagnosis) and at 3 and 6 weeks post-diagnosis. Sample size: 275 - Estimated using available data on diverticulitis and stratified data from FIT use in 2WW patients.

Interventions

DIAGNOSTIC_TESTFaecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome

Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis

Sponsors

GUTS - Fighting Bowel Cancer
CollaboratorUNKNOWN
Minimal Access Therapy Training Unit
CollaboratorOTHER
Royal Surrey County Hospital NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Computerised tomography diagnosis of acute diverticulitis * Participants capable of giving informed consent * Aged ≥ 18 years * Clinical decision for colonoscopy, flexible sigmoidoscopy or CT colonoscopy follow-up after diverticulitis diagnosis

Exclusion criteria

* Paediatric patients (\<18 years) * Not provided at least 1 faecal sample * Unable to/unwilling to provide informed consent * Withdrawal of consent for inclusion in study * Previous pan-proctocolectomy, subtotal colectomy surgery, or presence of stoma * Currently being treated for colorectal cancer * Mental health illness limiting compliance * Treated in hospital with colonic resection * Did not have colonoscopy, flexible sigmoidoscopy or CT colonoscopy

Design outcomes

Primary

MeasureTime frameDescription
Colorectal CancerDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of colorectal cancer on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.

Secondary

MeasureTime frameDescription
DiverticulitisDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of ongoing diverticular inflammation on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.
High risk adenomaDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of high risk adenoma on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.
Perianal diseaseDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of perianal disease on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.
Inflammatory bowel diseaseDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of inflammatory bowel disease on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.
Microscopic colitisDependant on timing of investigation but expected 6-12 weeksDiagnosis or absence of microscopic colitis on follow-up investigation (Colonoscopy, flexible sigmoidoscopy or CT colonography)and subsequent histology results if applicable.

Other

MeasureTime frameDescription
Faecal microbiome6 weeksResults of the microbiome run on the three faecal samples taken by the participant
Blood testsWill happen before CT diagnosing diverticulitisHaemoglobin and mean cell volume from routine blood tests when patient attended
Faecal calprotectin test result6 weeksResults of the three faecal calprotectin tests taken by the participant, ≥ 50 defined as positive
FIT (Faecal Immunochemical Test for haemoglobin) test result6 weeksResults of the three FIT tests taken by the participant, ≥ 10 defined as FIT positive

Countries

United Kingdom

Contacts

Primary ContactJames Norman, BMBS, MRCP
j.norman1@nhs.net+44 (0) 1483 688691
Backup ContactLaura Gordon
laura.gordon2@nhs.net+44 (0)1483686729

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026